Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATI355 (NG-101) antibodies against Nogo-A in acute cervical spinal cord injury
2016-001227-31Phase 2Completed
- Sponsor
- University of Zurich
- Start
- Jun 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of ATI-355 in Spinal cord injury (SCI), sponsored by University of Zurich. Primary endpoint: Upper extremity motor scores (UEMS). Started Jun 2018; status: completed.
02
Drugs
ATI-355
03
Conditions
Spinal cord injury (SCI)
Beyond the preview
Go deeper on 2016-001227-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001227-31.